In the News

At the 2016 American Association for Cancer Research (AACR) conference, there were clear signs that cancer treatment is evolving from a slash-and-burn method to a more precisely targeted, intelligent approach.

Scientists have learned that cutting a T cell’s brakes can have unexpected consequences.

A collaboration between MSK and Weill Cornell Medicine discovered a new relationship between cancer cells and the immune system, and shows how cancer can selfishly hijack a normally helpful immune pathway.

Learn how radiation oncologists at Memorial Sloan Kettering are making radiation therapy for metastatic cancer more effective, with fewer side effects, including a new advance called ECHO.

The third annual research symposium introduces high school students and teachers to several topics in cancer research.

New MSK research uncovers clues about how cells control a key DNA repair protein; develops a new method for studying gene amplifications in cancer; sheds new light on tumor suppressor genes; shows MSK-IMPACT® could be used for HLA genotype screening to predict response to cellular therapies; identifies a possible strategy to overcome immune evasion in ovarian cancer; and finds strong support for telemedicine visits among cancer patients.

Sometimes a BRCA mutation is just along for the ride, rather than driving a tumor’s development.

Twenty years ago, Charles Sawyers played a pivotal role in the development of Gleevec, a game-changing cancer drug that has gone on to save millions of lives and open doors for research and innovation. In this episode, Dr. Diane Reidy-Lagunes talks with Dr. Sawyers about what’s next in the field of cancer pharmaceuticals. Is another silver bullet on the horizon?